Dr. Kent F. Hoskins
Claim this profileUniversity of Illinois
Studies Breast Cancer
Studies Breast cancer
10 reported clinical trials
19 drugs studied
Area of expertise
1Breast Cancer
HER2 negative
Stage IV
HER2 positive
2Breast Cancer
HER2 negative
HER2 positive
ER positive
Affiliated Hospitals
Clinical Trials Kent F. Hoskins is currently running
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Tamoxifen
for Breast Cancer Risk Reduction
This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. Increasing breast density is a well established risk factor for breast cancer. Tamoxifen is a selective estrogen receptor modulator. It works by blocking the effects of the hormone estrogen in the breast. Tamoxifen has been shown to reduce breast density, even at reduced dosages, and is approved for the prevention of breast cancer.
Recruiting1 award Phase 2
More about Kent F. Hoskins
Clinical Trial Related1 year of experience running clinical trials · Led 10 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Kent F. Hoskins has experience with
- Cyclophosphamide
- Doxorubicin
- Paclitaxel
- Carboplatin
- Regional Nodal XRT
- Chestwall XRT
Breakdown of trials Kent F. Hoskins has run
Breast Cancer
Breast cancer
Cancer
Lobular Carcinoma in Situ
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kent F. Hoskins specialize in?
Kent F. Hoskins focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved HER2 negative patients, or patients who are Stage IV.
Is Kent F. Hoskins currently recruiting for clinical trials?
Yes, Kent F. Hoskins is currently recruiting for 6 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Kent F. Hoskins has studied deeply?
Yes, Kent F. Hoskins has studied treatments such as Cyclophosphamide, Doxorubicin, Paclitaxel.
What is the best way to schedule an appointment with Kent F. Hoskins?
Apply for one of the trials that Kent F. Hoskins is conducting.
What is the office address of Kent F. Hoskins?
The office of Kent F. Hoskins is located at: University of Illinois, Chicago, Illinois 60612 United States. This is the address for their practice at the University of Illinois.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.